Strategic partnerships Myriad Genetics collaborates with notable biotech leaders like AstraZeneca and SOPHiA GENETICS on genomics-based initiatives such as PrGIS, signaling strong affinity for co-development and validation projects that open doors for joint testing, data sharing, and expanded biomarker validation ventures.
Clinical expansion Recent activity highlights a focus on precision oncology and biomarker-driven treatment decisions, suggesting opportunities to upsell advanced molecular tests and integrated diagnostic solutions to oncology centers and academic medical networks seeking comprehensive genomic profiling.
AI enablement The company has invested in AI-enabled revenue-cycle tools and has a history of refining AI prompts to improve output accuracy, indicating potential for selling AI-assisted workflow optimization, automated reporting, and enhanced data interoperability services.
Cost efficiency Guidance reductions and reimbursement pressure imply a need for value-based offerings, such as bundled testing packages, payer-optimized reimbursement support, and cost-to-care analytics to help customers demonstrate ROI and sustain test adoption.
Digital processing Past collaboration on Image Genius with PwC demonstrates a track record in intelligent document processing and data extraction from pathology reports, presenting opportunities to offer complementary data-automation tools, integration services, and enhanced data capture for client labs.